Merck's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Merck develops medicines, vaccines, biologic therapies, consumer care and animal health products.

Merck's headquarters is...
Read more

Based on data from Merck's latest SEC filings

Annual Revenue

Based on data from Merck's latest SEC filings

Employees

Kenneth C. Frazier's photo - Chairman & CEO of Merck

Chairman & CEO

Kenneth C. Frazier

CEO Approval Rating

59/100

OVERVIEW

Founded:

1891

Headquarters:

KenilworthNew Jersey

Status:

PublicIndependent Company of NYSEMRK

Industry Sector:

Pharmaceuticals

SIC Code:

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Eli Lilly a competitor of Merck?

Want more news like this in your inbox? Get access for free

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

AbbVie is perceived as one of Merck's biggest rivals. AbbVie was founded in 2012, and its headquarters is in North Chicago, Illinois. Like Merck, AbbVie also works within the Pharmaceuticals field. AbbVie has 39,000 fewer employees than Merck.

Amgen is one of Merck's top rivals. Amgen is a Public company that was founded in 1980 in Thousand Oaks, California. Amgen competes in the Biotechnology field. Compared to Merck, Amgen has 48,000 fewer employees.

AstraZeneca is Merck's #3 rival. AstraZeneca is a Public company that was founded in Cambridge, England in 1999. Like Merck, AstraZeneca also competes in the Pharmaceuticals sector. AstraZeneca has 7,900 fewer employees vs. Merck.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Kenneth C. Frazier

Chairman & CEO

- -
69,000
$0
$44.4B
1

Richard A. Gonzalez

Chairman & CEO

54/100
30,000
- -
$32.6B
2

Robert A. Bradway

Chairman & CEO

67/100
19,200
$19M
$23.6B
3

Pascal Soriot

CEO

72/100
59,700
- -
$21.9B
4

Giovanni Caforio

Chairman & CEO

74/100
23,300
- -
$23.9B
5

Alex Gorsky

Chairman & CEO

66/100
135,100
- -
$81.3B
6

David A. Ricks

Chairman & CEO

67/100
38,680
- -
$24.7B
7

Emma Walmsley

CEO

71/100
99,827
- -
$39.4B
8

Vasant Narasimhan

CEO

81/100
118,393
- -
$50.3B
9

Albert Bourla

CEO

60/100
92,400
- -
$53.7B
10

Severin Schwan

CEO

54/100
94,052
- -
$932.5M

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$44.4B

Merck's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 36.1B. Over the last four quarters, Merck's revenue has grown by 8.9%. Specifically, in Q2 2019's revenue was $11.8B; in Q1 2019, it was $10.8B; in Q4 2018, it was $11B; in Q3 2018, Merck's revenue was $10.8B.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Tilos Therapeutics, Inc.

Jun 2019

Source »
$773M
Tilos develops and commercializes antibody therapeutics for the treatment of cancer, fibrosis, and autoimmunity.
Peloton Therapeutics, Inc.

May 2019

Source »
$1.1B
Peloton Therapeutics develops novel small molecule therapies for the treatment of cancer.
Immune Design Corp.

Feb 2019

Source »
$300M
Immune Design develops immunotherapy product candidates for the treatment of cancer and chronic diseases.
Viralytics Limited

Feb 2018

Source »
$394M
Viralytics focuses on the development of oncolytic immunotherapies for the treatment of cancer.
Rigontec GmbH

Sep 2017

Source »
$136.9M
Rigontec develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

These are all the companies that Merck has acquired. Merck has acquired 14 companies and its latest acquisition was Tilos Therapeutics, Inc. in Jun 2019. Tilos develops and commercializes antibody therapeutics for the treatment of cancer, fibrosis, and autoimmunity.

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Themis is a biopharmaceutical firm that develops prophylactic vaccines for the treatment of infectious diseases.
$44M
Sep 17, 2019
Series D
-
Navigating Cancer develops a patient relationship management platform that offers personalized care management services for patients and oncologists.
$26M
Mar 18, 2019
Series D
-
Moderna researches, develops and markets messenger RNA therapeutics for genetic disorders, hemophilic blood factors and oncology treatments.
$125M
May 02, 2018
Series H
Dec 06, 2018
SerImmune is a biotechnology company that researches and develops therapeutics for autoimmune diseases.
$8M
Jun 19, 2017
Equity
-
GRAIL is a provider of blood-based DNA screening test for the detection of cancer.
$1.2B
Feb 27, 2017
Series B
Jan 01, 2016

These are all the companies that Merck has invested in. Merck has invested 14 companies and its latest investment was Tilos Therapeutics, Inc. in Jun 2019. Tilos develops and commercializes antibody therapeutics for the treatment of cancer, fibrosis, and autoimmunity.

Merck News

October 8, 2019FierceBiotechIT

Merck taps 4D pharma for bacterial vaccine R&D project

Merck has teamed up with 4D pharma to develop bacterial strains as vaccines. The deal gives Merck the... See more »
October 8, 2019Sharecast

4D Pharma inks research collaboration agreement with Merck & Co

4D Pharma has entered into a research collaboration agreement with Merck & Co to discover and develop... See more »
October 7, 2019CITEworld

Merck proves 3D printing's transformative power

3D printing has proven transformative in industries ranging from automotive to aerospace. But can it ... See more »
October 4, 2019BioPortfolio

Merck's Keytruda Approved as Monotherapy for Lung Cancer in China

MerckMSD announced China approval of Keytruda the company's antiPD1 immunotherapy as a firstline mono... See more »
October 3, 2019Zacks

Merck's Pediatric Filings for Dificid Get FDA's Priority Review

The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of ... See more »
October 3, 2019PT Community

Merck Announces Promising Results for Keytruda in Triple-Negative Breast Ca Patients

Patients with high-risk, early-stage triple-negative breast cancer have a statistically significant i... See more »

Merck Press Releases

August 14, 2019Business Wire

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary ... See more »
July 8, 2019StreetInsider

Merck Manuals Offers Guidance on Eliminating Asthma Triggers

Asthma is one of the most prevalent chronic conditions afflicting children in the United States, and ... See more »
May 16, 2019PR Newswire

Intec Pharma Announces Research Collaboration Agreement With Merck

NEW YORK, May 16, 2019 /PRNewswire/ --Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") tod... See more »
May 13, 2019PR Newswire

Merck Manuals Launches "Medical Mythbusters" Podcast to Set the Record Straight on Medical Legends, Misinformation

KENILWORTH, N.J., May 13, 2019 /PRNewswire/ -- Merck Manuals, one of the world's most widely used med... See more »
April 2, 2019PR Newswire

BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy

BERGEN, Norway, April 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) announces that the first pat... See more »
April 1, 2019Business Wire

ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company fo... See more »
March 15, 2019U Wire

Merck CEO Kenneth Frazier

Merck & Co., Inc. Chairman and CEO Kenneth C. Frazier will be speaking at Drexel's 2019 commencement ... See more »

Merck Videos

Social Statistics

Headquarters

2000 Galloping Hill Road

Kenilworth, New Jersey07033

1-908-740-4000

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Merck & Co., Inc. (NYSE: MRK) develops medicines, vaccines, biologic therapies, consumer care, and animal health products. It is known as Merck, Sharp & Dohme (MSD) outside of the US and Canada and it is an American pharmaceutical company. It was esta...

CEO

Merck's Chairman & CEO, Kenneth C. Frazier, currently has an approval rating of 59%. Merck's primary competitors are AbbVie, Amgen & AstraZeneca.

Website

merck.com

Frequently Asked Questions about Merck

  1. When was Merck founded?

    Merck was founded in 1891
  2. Who is Merck's CEO?

    Merck's CEO is Kenneth C. Frazier
  3. How much revenue does Merck generate?

    Merck generates $44.4B in revenue
  4. How much funding does Merck have?

    Merck has historically raised $0 in funding
  5. Where is Merck's headquarters?

    Merck's headquarters is in Kenilworth New Jersey, USA
  1. How many employees does Merck have?

    Merck has 69,000 employees
  2. What sector does Merck operate in?

    Merck is in Pharmaceuticals
  3. Who are Merck's competitors?

    Merck's top competitors are AbbVie, Amgen, AstraZeneca
  4. Who has Merck invested in?

    Merck's has invested in companies such as Themis, Navigating Cancer, Moderna